Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma BiomarkersNiklas Mattsson, Oskar Hansson, Karly Alex Cody et al.|JAMA Neurology|2023Cited by 293
Association of Age at Menopause and Hormone Therapy Use With Tau and β-Amyloid Positron Emission TomographyGillian Coughlan, Rachel F. Buckley, Tobey J. Betthauser et al.|JAMA Neurology|2023Cited by 124
Prevalence and Clinical Implications of a β-Amyloid–Negative, Tau-Positive Cerebrospinal Fluid Biomarker Profile in Alzheimer DiseasePontus Erickson, Prashanthi Vemuri, Joel Simrén et al.|JAMA Neurology|2023Cited by 46
The cerebrospinal fluid A‐T+ Alzheimer disease biomarker profile: prevalence and clinical relevancePontus Eriksson, Henrik Zetterberg, Joel Simrén et al.|Alzheimer s & Dementia|2023Cited by 2